Visit Contract Pharma
at Booth #1921

Charles River, Distributed Bio in Exclusive Antibody Discovery Pact

10.25.18

Gains access to Distributed Bio’s antibody libraries and integrated antibody optimization technologies

Charles River Laboratories International, Inc. has entered into an exclusive partnership with Distributed Bio, Inc., a provider of computational design and optimization of antibody discovery platforms.
 
The partnership grants Charles River’s clients access to Distributed Bio’s antibody libraries and integrated antibody optimization technologies. Distributed Bio’s libraries are computationally optimized for both sequence diversity and engineering fitness through the analysis of thousands of human antibody repertoires and all known monoclonal therapeutics in clinical trials. A combination of Distributed Bio’s antibody libraries and Charles River’s drug development expertise aims to create a unique platform for therapeutic antibody discovery and development.

“Distributed Bio’s technology, coupled with Charles River’s deep scientific strength in drug discovery and early-stage development, ensures that our portfolio is truly next generation. This combination provides our clients with Distributed Bio’s ability to discover new antibodies, then proceed seamlessly from hit to clinical candidate faster than before,” said Birgit Girshick, corporate executive vice president of Discovery and Safety Assessment at Charles River.